GLP-1 receptor agonists such as semaglutide and tirzepatide are currently the most effective non-surgical weight loss treatments available. In large randomized trials, semaglutide produced an average 14.9 percent reduction in body weight over 68 weeks, and tirzepatide produced up to 20.9 percent over 72 weeks. They work by correcting the hormonal signaling that drives hunger, not by forcing willpower. The evidence also shows that outcomes depend heavily on what surrounds the medication: protein intake, resistance training, gut support, nutrient monitoring, and a maintenance plan. At Portland Clinic of Natural Health, Dr. Maria Reebs, DNP, FNP, provides medically supervised GLP-1 therapy inside a full integrative metabolic program.
For decades, weight loss advice in Oregon and everywhere else came down to some version of eat less and move more. That advice failed most people, not because they lacked discipline, but because body weight is defended by a powerful hormonal system that resists caloric restriction. When you lose weight through diet alone, hunger hormones rise, satiety hormones fall, and the body works to restore what it lost.
GLP-1 receptor agonists are the first widely available medications that intervene directly in that system. Glucagon-like peptide-1 is a hormone your intestinal L-cells release after you eat. It triggers glucose-dependent insulin release from the pancreas, slows gastric emptying, and acts on appetite centers in the brain to signal that you have had enough. GLP-1 medications extend and amplify that natural signal.
The result is not a stimulant effect and not a laxative effect. It is a restoration of a satiety signal that, in many people with metabolic dysfunction, has been blunted for years.
Below are the five reasons the clinical evidence supports GLP-1 therapy as one of the most powerful weight loss tools currently available, followed by the reasons why the integrative context in which it is prescribed determines whether the results last.
This is the headline finding, and it holds up under scrutiny.
In the STEP 1 trial, 1,961 adults with overweight or obesity and without diabetes received once-weekly semaglutide 2.4 mg or placebo alongside a lifestyle intervention. At 68 weeks, the semaglutide group lost an average of 14.9 percent of body weight compared with 2.4 percent on placebo, and 86 percent of participants achieved at least 5 percent weight loss.
In the SURMOUNT-1 trial, 2,539 adults received tirzepatide, a dual GIP and GLP-1 receptor agonist, or placebo for 72 weeks. Average weight reduction was 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg, compared with 3.1 percent on placebo. In the 15 mg group, 57 percent of participants lost at least 20 percent of their body weight.
For perspective, older weight loss medications typically produced reductions in the range of 3 to 10 percent depending on the agent. Intensive lifestyle programs alone generally produce 5 to 8 percent, with substantial regain over time. GLP-1 and dual incretin therapies moved the ceiling into territory that previously required bariatric surgery.
One of the most common experiences patients describe after starting GLP-1 therapy is the quieting of what researchers now informally call food noise, the persistent intrusive preoccupation with eating.
Mechanistically, GLP-1 receptor agonists act on hypothalamic and brainstem circuits governing hunger and reward, slow gastric emptying so meals feel satisfying for longer, enhance glucose-dependent insulin secretion, and suppress inappropriate glucagon release. These are not psychological interventions. They are physiologic corrections.
Clinically, this reframes the entire conversation. A patient who has spent twenty years being told to try harder discovers that when the hormonal signal is restored, the behaviors they were told to adopt suddenly become achievable. That shift in self-understanding is itself therapeutic, and it is one of the most important things an integrative provider can help a patient process.
Weight is a proxy. Metabolic health is the actual goal, and GLP-1 therapy improves multiple markers simultaneously.
Across the clinical trial literature, GLP-1 receptor agonists have been associated with reductions in visceral and ectopic fat, improvements in fasting glucose, HbA1c, and insulin sensitivity, reductions in triglycerides and LDL cholesterol, lowered systolic blood pressure, decreased markers of systemic inflammation such as C-reactive protein, and improvement in hepatic steatosis.
The most significant outcome data came from the SELECT trial, which enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Over a mean follow-up of approximately 40 months, semaglutide reduced the composite risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20 percent compared with placebo, with events occurring in 6.5 percent of the semaglutide group versus 8.0 percent on placebo.
That is a hard cardiovascular endpoint, not a surrogate marker. It moves GLP-1 therapy out of the cosmetic category and into the category of preventive metabolic medicine, which is precisely how it should be framed.
GLP-1 medications have now been studied in tens of thousands of patients across roughly two decades of clinical use, initially for type 2 diabetes and subsequently for chronic weight management. That depth of data is unusual for a newer drug class and it means both the benefits and the risks are reasonably well mapped.
The most common adverse effects are gastrointestinal: nausea, constipation, diarrhea, reflux, and early satiety. These are usually dose-dependent, most pronounced during titration, and largely manageable with proper dose escalation, meal composition changes, hydration strategy, and targeted digestive support.
There are real contraindications and cautions that require a prescribing clinician who knows the patient. Semaglutide, liraglutide, and tirzepatide carry a boxed warning regarding thyroid C-cell tumors based on rodent data, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. They are not appropriate during pregnancy or when attempting conception. They require careful evaluation in patients with a history of pancreatitis, gallbladder disease, gastroparesis, or eating disorders. They are indicated for patients meeting specific BMI and comorbidity criteria, not for patients seeking modest cosmetic weight loss.
This is exactly why the prescriber matters. A brief intake form and an automatic shipment is not medical care.
This is the reason most often left out of the marketing, and it is the one that predicts long-term success.
Every major trial studied these medications as an adjunct to lifestyle intervention, never as a standalone therapy. The STEP 3 trial took that further by giving all 611 participants intensive behavioral therapy, meaning 30 counseling visits with a registered dietitian plus an initial low-calorie diet. Participants receiving semaglutide alongside that program lost 16.0 percent of body weight at 68 weeks compared with 5.7 percent for those receiving behavioral therapy plus placebo. Two things are worth noting there. The medication roughly tripled what an intensive lifestyle program achieved on its own, and the placebo group still lost meaningful weight through behavioral support alone.
The corollary is equally important. In the STEP 1 trial extension, participants who discontinued semaglutide regained roughly two-thirds of their lost weight within one year, with cardiometabolic markers drifting back toward baseline. The STEP 4 trial demonstrated the reverse: after 20 weeks of run-in treatment, continuing semaglutide produced further weight loss, while switching to placebo produced steady regain.
The conclusion the researchers drew is the same one integrative clinicians have been making for years. Obesity behaves like a chronic condition. GLP-1 medications manage it well while they are being used within a structured program. They do not cure the underlying metabolic environment, and they were never designed to. What you build around the medication is what you keep.
Here is where the difference between a prescription and a program becomes clinically meaningful.
Protecting lean muscle mass. This is the single most important issue in GLP-1 therapy and the most frequently neglected. A systematic review and network meta-analysis of 22 randomized controlled trials found that lean mass loss comprised approximately 25 percent of total weight lost on GLP-1 receptor agonists, and that the most potent agents, tirzepatide 15 mg and semaglutide 2.4 mg, were the most effective for fat loss but among the least effective at preserving lean mass. Losing muscle lowers resting metabolic rate, reduces functional strength, and increases the likelihood of regain. The evidence-supported countermeasures are adequate protein intake and progressive resistance training, both of which require deliberate planning when appetite is suppressed.
Nutrient adequacy when you are eating less. When total intake falls substantially, micronutrient intake falls with it. Iron, B12, vitamin D, magnesium, calcium, and essential fatty acids all warrant attention. Integrative care means baseline and follow-up labs, not guesswork.
Managing the gastrointestinal side effects properly. Delayed gastric emptying, constipation, and reflux are common and are among the most frequent reasons patients quit. Meal structure, fiber sequencing, hydration, bile support, digestive enzymes, magnesium, and appropriate probiotic strategy can make the difference between tolerating the medication and abandoning it in month two.
Looking at the whole metabolic picture. Thyroid function, insulin resistance, cortisol patterns, sex hormones, perimenopausal metabolic shifts, sleep quality, and inflammatory drivers all influence how a patient responds. Weight resistance in a 47-year-old woman with subclinical hypothyroidism and disrupted sleep is a different clinical problem than weight gain in a 34-year-old with insulin resistance, even if the prescription looks the same.
Planning the exit before you need it. Because the trial data on discontinuation is unambiguous, the maintenance strategy should be designed at the start, not improvised at month twelve. That includes body composition tracking, strength benchmarks, dose tapering considerations, and a nutrition framework the patient can sustain independently.
Dr. Maria Reebs is a board-certified family nurse practitioner with a Doctor of Nursing Practice degree, practicing at Portland Clinic of Natural Health with a clinical focus on metabolic medicine, women's health, and hormone balance. She provides medically supervised GLP-1 therapy for patients across Portland, Tigard, Beaverton, Lake Oswego, and the surrounding Oregon communities.
What distinguishes her approach is that the medication is one component of a monitored program rather than the entire intervention. Patients receive:
Her work sits alongside the broader integrative and naturopathic care available at Portland Clinic of Natural Health, so patients with complex chronic illness, autoimmunity, hormonal dysregulation, or environmental illness are not siloed into a single-issue weight loss protocol.
To schedule a metabolic and weight management consultation, contact Portland Clinic of Natural Health.
How much weight can I expect to lose on a GLP-1 medication?
In clinical trials, average loss was approximately 15 percent of body weight with semaglutide over 68 weeks and up to approximately 21 percent with tirzepatide over 72 weeks. Individual results vary considerably based on dose, adherence, baseline metabolic status, nutrition, and activity level.
Will I regain the weight if I stop?
Some regain is likely without a structured plan. In the STEP 1 trial extension, participants regained about two-thirds of lost weight within a year of stopping. This is why maintenance planning, muscle preservation, and sustainable nutrition are built into treatment from the beginning rather than added at the end.
Do GLP-1 medications cause muscle loss?
Some lean mass loss occurs with any significant weight reduction. Meta-analysis data suggest roughly 25 percent of total weight lost on GLP-1 therapy comes from lean mass, though that same analysis found lean mass as a percentage of body composition was largely preserved. Adequate protein intake and resistance training are the primary evidence-supported strategies to protect muscle.
Are these medications safe long term?
GLP-1 receptor agonists have been in clinical use since 2005 for type 2 diabetes and have accumulated a substantial safety record. They are not appropriate for everyone. Contraindications include a personal or family history of medullary thyroid carcinoma or MEN2, pregnancy, and certain gastrointestinal and pancreatic conditions. Candidacy should be assessed by a qualified prescribing clinician.
Can I take a GLP-1 medication if I am already working with a naturopathic doctor?
Yes, and ideally the care is coordinated. Integrative and conventional approaches are complementary here. Nutritional support, gut health, hormone evaluation, and metabolic optimization make GLP-1 therapy work better, not worse.
Does insurance cover this?
Portland Clinic of Natural Health participates with a number of insurance plans for medical visits, and our team can verify your benefits before your first appointment. Coverage for the medication itself is a separate question and varies widely between plans. Many commercial policies cover GLP-1 agents for type 2 diabetes but exclude or restrict them for weight management, and requirements such as prior authorization or documented BMI thresholds are common. We will tell you what your specific plan covers before you commit to treatment.
How is this different from a telehealth GLP-1 subscription?
Direct-to-consumer programs typically provide a prescription with minimal evaluation, no laboratory monitoring, no body composition tracking, and no maintenance plan. Medically supervised integrative care addresses the metabolic terrain the medication is operating within.
This article is intended for general educational purposes and does not constitute medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with specific indications, contraindications, and risks. They are not appropriate for all patients. Do not start, stop, or change any medication without consulting a qualified healthcare provider who has evaluated your individual medical history. If you are pregnant, attempting to conceive, breastfeeding, or have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, gallbladder disease, gastroparesis, or an eating disorder, discuss these conditions with your provider before considering GLP-1 therapy.
